Request a copy

Full Text

• Walko CM, Lindley C, Hill C, Carolina N (2008) Capecitabine: a review. Clin Ther 27:23–44
• Cassidy J, Saltz L, Twelves C et al (2011) Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol 22:2604–2609. doi:10.1093/annonc/mdr031
• Thorn CF, Marsh S, Carrillo MW et al (2011) PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 21:237–242. doi:10.1097/FPC.0b013e32833c6107
• Thomas F, Motsinger-Reif AA, Hoskins JM et al (2011) Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 105:1654–1662. doi:10.1038/bjc.2011.442
• van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939–950. doi:10.1016/j.ejca.2003.12.004
• Martinez-Balibrea E, Abad A, Martínez-Cardús A et al (2010) UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 103:581–589. doi:10.1038/sj.bjc.6605776
• Deenen MJ, Tol J, Burylo AM et al (2011) Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17:3455–3468. doi:10.1158/1078-0432.CCR-10-2209
• Loganayagam A, Arenas Hernandez M, Corrigan A et al (2013) Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 108:2505–2515. doi:10.1038/bjc.2013.262
• Pander J, Wessels JAM, Gelderblom H et al (2011) Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann Oncol 22:1147–1153. doi:10.1093/annonc/mdq572
• Joerger M, Huitema AD, Boot H et al (2015) Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 75:763–772. doi:10.1007/s00280-015-2698-7
• Pullarkat ST, Stoehlmacher J, Ghaderi V et al (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65–70
• Lecomte T, Ferraz J-M, Zinzindohoué F et al (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880–5888. doi:10.1158/1078-0432.CCR-04-0169
• Schwab M, Zanger UM, Marx C et al (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol 26:2131–2138. doi:10.1200/JCO.2006.10.4182
• Rosmarin D, Palles C, Church D et al (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32:1031–1039. doi:10.1200/JCO.2013.51.1857
• Lostia AM, Lionetto L, Ialongo C et al (2009) A liquid chromatography-tandem mass spectrometry method for the determination of 5-fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit 31:482–488. doi:10.1097/FTD.0b013e3181ae4516
• Mazzuca F, Borro M, Botticelli A et al (2016) Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. Oncotarget 7:20612–20620. doi:10.18632/oncotarget.7991
• Etienne-Grimaldi M-C, Milano G, Maindrault-Goebel F et al (2010) Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 69:58–66. doi:10.1111/j.1365-2125.2009.03556.x
• Ruzzo A, Graziano F, Loupakis F et al (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8:278–288. doi:10.1038/sj.tpj.6500463
• Braun MS, Richman SD, Thompson L et al (2009) Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27:5519–5528. doi:10.1200/JCO.2008.21.6283
• Milano G, Etienne-Grimaldi M-C, Mari M et al (2008) Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 66:88–95. doi:10.1111/j.1365-2125.2008.03159.x
• Sharma R, Hoskins JM, Rivory LP et al (2008) Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 14:817–825. doi:10.1158/1078-0432.CCR-07-0425
• Romiti A, Roberto M, D’Antonio C et al (2016) The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer. Anti-Cancer Drugs. doi:10.1097/CAD.0000000000000429